Alk­er­mes plots course to the FDA af­ter its de­pres­sion drug scores suc­cess in last-stand PhI­II

Just af­ter the start of this year, Alk­er­mes was blast­ed by the news that the first two of three late-stage stud­ies for its de­pres­sion drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.